EnzymeBioSystems Announces an Independent Research Group Reported Breast Cancer Preventive Efficacy for a Novel Synthetic Triterpenoid

LAS VEGAS, November 17, 2014 /PRNewswire/ -- EnzymeBioSystems (OTCBB: ENZB) announces, methyl amooranin, its lead pharmaceutical product, shows promise in preventing breast cancer.  Based on preclinical research lead by Dr. Anupam Bishayee, Associate Professor, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA, methyl amooranin markedly inhibited breast tumor formation in an animal model of breast cancer that mimics human disease.  The results were published by the peer-reviewed journal International Journal of Cancer (September 1, 2013 edition).  Two additional published studies from Dr. Bishayee's laboratory also looked at possible mechanisms of action of this promising compound in preventing breast cancer.  Dr. Bishayee's research was supported by a grant from National Institutes of Health (NIH)/National Cancer Institute (NCI).

"Breast cancer is one of the most frequently diagnosed cancers and major causes of death in women in the world," indicated by Dr. Bishayee.  "According to the American Cancer Society, about 233,000 new cases of invasive mammary cancer will be diagnosed in women in the year 2014 alone and 40,000 women will die from this disease in the same year," Dr. Bishayee said.

Methyl amooranin, a structurally modified version of a plant-based natural product, could be developed as a preventive drug to reduce the risk of human breast cancer that remains a devastating disease. 

Management is in the process of preparing the required studies to apply for an Investigational New Drug Application ("IND") with the FDA. 

"It is still too early to determine if this project has any potential value for the company, and there are no assurances that the company will ever obtain an IND for this compound," stated Gary Rojewski, CEO of EnzymeBioSystems.

The content of this release is solely the responsibility of the EnzymeBioSystems and does not necessarily represent the official views of the NCI or the NIH.

About EnzymeBioSystems

EnzymeBioSystems produces specialty enzymes and enzyme related products.  The Company plans to use enzyme technologies to develop commercial solutions for a broad range of applications within the pharmaceutical industry. 

Included in this release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct.  The company's actual results could differ materially from those anticipated in the forward-looking statements.

Contact: Edward Zimmerman III
Phone:  +1-(702) 631-4251
[email protected]

SOURCE EnzymeBioSystems